To observe the clinical efficacy and safety of ezetimibe tablets or alirocumab injection in conjunction with rosuvastatin calcium tablets for the treatment of coronary heart disease (CHD).

Patients with CHD were randomly divided into two groups. Both groups took rosuvastatin calcium tablets, 10 mg once daily. The control group additionally received ezetimibe tablets,10 mg once daily, while the treatment group received alirocumab injection (subcutaneous injection, 75 mg per dose, once every two weeks). After 6 months of treatment, the two groups were compared in terms of clinical efficacy, lipid metabolism, cardiac function and myocardial injury markers. Adverse drug reactions during treatment were recorded.

This study enrolled a total of 118 patients, with 59 assigned to treatment group and 59 to the control group. During the 6-month treatment period, 4 patients in the control group dropped out due to changes in their condition. In treatment group, 6 patients dropped out, comprising 3 due to changes in the treatment plan and 3 who voluntarily withdrew from the study midway. Ultimately, 55 patients in the control group and 53 in the treatment group were included in the final analysis. After treatment, the total clinical effective rates were 90.57% (48 cases/53 cases) in treatment group and 72.73% (40 cases /55 cases) in control group, with statistically significant difference (P<0.05). After treatment, the cholesterol levels in the treatment and control groups were (2.58±0.40) and (3.60±0.52) mmol·L^-1, respectively; low-density lipoprotein cholesterol levels were (2.16±0.36) and (2.51±0.44) mmol·L^-1, respectively; N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were (301.12±20.11) and (326.54±25.84) pg·mL^-1, respectively; cardiac troponin Ⅰ (cTnⅠ) levels were (0.53±0.19) and (0.90±0.26) μg·L^-1, respectively; matrix metalloproteinase-9 (MMP-9) levels were (31.04±4.05) and (37.25±4.72) ng·mL^-1, respectively; left ventricular ejection fraction (LVEF) were (49.79±5.33)% and (45.09±5.21)%, respectively; left ventricular end-diastolic diameter (LVEDD) were (50.36±3.23) and (55.11±3.48) mm, respectively; and left ventricular end-systolic diameter (LVESD) were (35.04±3.72) and (40.64±3.97) mm, respectively. The aforementioned indicators in treatment group showed statistically significant differences compared to control group (all P<0.05). Adverse drug reactions in control group included 2 cases of nausea and vomiting, 2 cases of diarrhea, 3 cases of fatigue and 2 cases of arthralgia. Treatment group reported 2 cases of nausea and vomiting, 3 cases of diarrhea, 2 cases of fatigue, 1 case of arthralgia and 2 cases of injection site redness and swelling. The overall incidence rates of adverse drug reactions in treatment and control groups were 18.87% (10 cases/53 cases) and 16.36% (9 cases/55 cases), respectively, with no statistically significant difference (P>0.05).

Both ezetimibe tablets and alirocumab injection demonstrate good therapeutic efficacy in the treatment of coronary heart disease. However, the combination of alirocumab injection with rosuvastatin calcium tablets can further improve lipid metabolism and cardiac function.

To observe the clinical efficacy and safety of cinacalcet tablets combined with calcitriol pills in diabetic nephropathy (DN) patients undergoing hemodialysis.

DN patients receiving hemodialysis in our hospital were divided into treatment group and control group based on different medication regimens. The control group was treated with calcitriol pills, administered orally twice a week. The dosage was 0.25-1.5 μg for patients with intact parathyroid hormone (iPTH) 300-600 ng·L^-1, 0.5-2.0 μg for those with (iPTH) 600-1 000 ng·L^-1, and 2.0-4.0 μg for those with iPTH > 1 000 ng·L^-1. The treatment group received cinacalcet tablets in addition to the control group’s treatment. The initial dose of cinacalcet tablet was 25 mg per day, adjusted every 2-4 weeks, the dose remained unchanged for patients with serum calcium < 2.1 mmol·L^-1; increased to 50 mg per day for those with serum calcium>2.0 mmol·L^-1; and decreased to 75 mg per day for those with serum calcium<1.8 mmol·L^-1. Both groups were treated for 6 months. Clinical efficacy, calcium-phosphorus metabolism, renal function, bone metabolism, iPTH levels and parathyroid gland volume were compared between the two groups, and safety was evaluated.

A total of 94 patients were included in this study, with 47 cases in each of treatment and control groups. After treatment, the total effective rates were 95.74% (45 cases/47 cases) in treatment group and 80.85% (38 cases /47 cases) in control group, showing statistically significant difference (P<0.05). After treatment, the blood calcium levels in treatment and control groups were (2.78±0.21) and (2.49±0.23) mmol·L^-1, respectively; blood phosphorus levels were (1.11±0.13) and (1.39±0.17) mmol·L^-1, respectively; calcium-phosphorus product levels were 3.09±0.24 and 3.46±0.29, respectively; fibroblast growth factor 23 (FGF23) levels were (60.55±7.21) and (71.62±7.84) ng·L^-1, respectively; alkaline phosphatase levels were (91.06±28.43) and (110.35±32.19) U·L^-1, respectively; osteoprotegerin levels were (6 892.43±395.46) and (7 142.58±411.27) ng·L^-1, respectively; iPTH levels were (623.08±57.19) and (721.57±61.46) ng·L^-1, respectively; and parathyroid gland volumes were (0.81±0.19) and (1.11±0.18) cm³, respectively. All of these indicators in treatment group showed statistically significant differences compared to control group (all P<0.05). The main adverse drug reactions in treatment group included pruritus (2 cases), myalgia (3 cases), nausea and vomiting (1 case) and diarrhea (1 case). In the control group, adverse drug reactions were pruritus (1 case), myalgia (2 cases), nausea and vomiting (2 cases) and diarrhea (1 case). The total incidence of adverse drug reactions were 12.77% (6 cases/47 cases) in treatment group and 14.89% (7 cases/47 cases) in control group, with no statistically significant difference (P>0.05).

The combination of cinacalcet tablets and calcitriol pills effectively corrects disorders of calcium-phosphorus and bone metabolism, reduces iPTH levels, and decreases parathyroid gland volume in DN patients on hemodialysis, with a favorable safety profile.

To investigate the effects of roxadustat capsules combined with multi-dimensional exercise rehabilitation training on microinflammation and vascular endothelial function in elderly hemodialysis patients.

Elderly patients who underwent regular dialysis and took roxadustat capsules were randomly divided into the treatment group and the control group according to the random number table. Patients in the control group took roxadustat capsules. Patients in the treatment group were given roxadustat capsules combined with multi-dimensional exercise rehabilitation training. For those weighing less than 60 kg, treated with roxadustat capsules 100 mg per time; for those weighing more than 60 kg, took roxadustat capsules 120 mg each time; three times a week. The multidimensional exercise included resistance exercise, aerobic exercise, and mindfulness meditation during dialysis, 3 times per week, 70 minutes each session, lasting 6 months. Clinical efficacy, microinflammatory factor indicators, endothelial function indicators, biochemical indicators, and adverse drug reactions were collected before and after the study.

A total of 235 cases were enrolled in this study. The treatment group included 115 cases. The control group included 120 cases. After the treatment, the total effective rates of the treatment group and the control group were 90.43% (104 cases /115 cases) and 79.17% (95 cases /120 cases), respectively, and the difference was statistically significant (P<0.05). The total effective rate in the non-diabetic patients of the treatment group was 94.38% (84 cases /89 cases), significantly higher than the 80.65% (75 cases / 93 cases) in the diabetic patients of the treatment group (P<0.05). After treatment, the levels of serum nuclear transcription factor (NF-κB) in the treatment and the control groups were (24.78±4.67) and (36.09±4.25) ng·L^-1, respectively; interleukin-6 (IL-6) levels were (25.38±4.24) and (28.47±4.62) ng·L^-1; interferon-γ (IFN-γ) levels were (40.66±4.89) and (50.01±5.95) ng·L^-1; serum endothelin-1 (ET-1) levels were (87.41±26.59) and (120.70±28.52) ng·L^-1; soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were (2 848.50±84.75) and (5 639.82±125.63) μg·L^-1; and plasma endothelial microparticles (EMP) counts were (95.43±20.19) and (110.55±26.78) per μL, respectively. The above indicators in the treatment group were statistically significantly different from those in the control group (all P<0.05). The main adverse drug reactions in the treatment group and the control group were nausea, vomiting, indigestion and fatigue. The total incidence of adverse drug reaction rates in the treatment group and the control group were 11.30% (13 cases /115 cases) and 11.67% (14 cases /120 cases), respectively. There was no statistically significant difference (P>0.05).

Roxadustat capsules combined with multidimensional exercise rehabilitation training has shown significant efficacy in microinflammation and vascular endothelial dysfunction in elderly hemodialysis patients, which can reduce microinflammatory responses and improve vascular endothelial function, outperforming the effects of roxadustat capsules alone, with good safety.

To explore the efficacy and safty of different administration routes of dexmedetomidine injection in elderly patients undergoing total hip arthroplasty (THA).

The elderly THA patients were randomly divided into the intravenous group (ID group, ropivacaine injection nerve block, 0.5 μg·kg^-1 dexmedetomidine injection administered by intravenous pump) and the perineural group (PD group, 0.5 μg·kg^-1 dexmedetomidine injection combined with ropivacaine injection nerve block). Compare the postoperative visual analog scale (VAS) scores, inflammatory factors, hemodynamic parameters, awakening time, incidence and duration of emergence agitation (EA), mini-mental state examination (MMSE) scores, riker sedation-agitation scale (RSAS), oxidative stress and immune function between the two groups and safty evaluation was conduated.

A total of 102 cases were included, 51 in the ID group and 51 in the PD group. At 48 hours after surgery, the resting VAS scores of ID group and PD group were (1.85±0.73) and (1.52±0.61) points, and the movement VAS scores were (3.61±0.64) and (3.27±0.42) points, respectively. The rest/movement VAS scores of PD group were significantly lower than those of ID group (all P<0.05). Immediately after surgery, C-reactive protein (CRP) in ID group and PD group were (6.80±1.03) and (6.13±0.75) mg·L^-1, interleukin-1β (IL-1β) were (8.06±0.87) and (6.07±0.63) pg·mL^-1, tumor necrosis factor-α (TNF-α) were (99.24±12.03) and (81.10±9.25) ng·mL^-1, interleukin-8 (IL-8) were (8.03±0.73) and (6.19±0.68) pg·mL^-1, interleukin-6 (IL-6) were (39.68±7.25) and (32.35±6.86) pg·mL^-1; 1 day after surgery, CRP in ID group and PD group were (6.07±1.07) and (5.37±0.81) mg·L^-1, IL-1β were (6.71±0.66) and (5.24±0.65) pg·mL^-1, TNF-α were (98.21±11.00) and (77.48±10.78) ng·mL^-1, IL-8 were (6.76±0.57) and (5.29±0.60) pg·mL^-1, IL-6 were (37.93±8.65) and (30.34±7.20) pg·mL^-1; 3 day after surgery, CRP in ID group and PD group were (5.53±1.04) and (5.06±0.64) mg·L^-1, IL-1β were (6.11±0.73) and (4.30±0.68) pg·mL^-1, TNF-α were (83.97±13.78) and (51.32±9.69) ng·mL^-1, IL-8 were (6.26±0.67) and (4.33±0.52) pg·mL^-1, IL-6 were (31.35±7.06) and (28.24±5.23) pg·mL^-1. The levels of CRP, IL-1β, TNF-α, IL-8 and IL-6 in PD group were statistically significantly lower than those in ID group immediately after operation, 1 day and 3 days after operation (all P<0.05). The recovery time of ID group and PD group was (28.93±3.00) and (25.93±2.91) min, respectively; the incidence of EA was 23.53% and 7.84%, respectively; the duration of EA was (2.32±0.38) and (1.82±0.36) days, respectively. Immediately after surgery, superoxide dismu-tase (SOD) in ID group and PD group were (136.47±16.96) and (154.81±15.38) U·mL^-1, malondialdehyde (MDA) were (8.89±1.24) and (6.54±1.13) nmol·mL ^-1, CD4⁺ were (29.28±2.94)% and (32.62±2.57)%, CD4⁺/CD8⁺ were (1.34±0.39)% and (1.55±0.37)%; 1 day after surgery, SOD in ID group and PD group were (149.82±17.54) and (157.73±16.52) U·mL^-1, MDA were (6.04±1.10) and (4.37±1.02) nmol·mL ^-1, CD4⁺ were (24.75±1.71)% and (28.36±2.31)%, CD4⁺/CD8⁺ were (1.24±0.31)% and (1.37±0.33)%; 3 day after surgery, SOD in ID group and PD group were (156.44±19.73) and (164.39±19.15) U·mL^-1, MDA were (5.27±0.95) and (4.05±0.68) nmol·mL ^-1, CD4⁺ were (27.35±1.78)% and (31.16±2.33)%, CD4⁺/CD8⁺ were (1.22±0.35)% and (1.43±0.40)%. SOD、CD4⁺、CD4⁺/CD8⁺ in PD group were statistically significantly higher than those in ID group (all P<0.05), MDA was statistically significantly lower than that in ID group (P<0.05). Among the routes of administration, ID was a risk factor for EA during general anesthesia in THA in elderly patients (P<0.05). Among the administration doses, different administration doses did not increase the risk of EA during general anesthesia in elderly patients with THA (P>0.05).

Compared with intravenous administration, peripheral dexmedetomidine injection can effectively reduce the incidence of EA, reduce inflammation and oxidative stress, improve analgesia and immune function in elderly patients with THA, and the effect can be achieved at a lower dose, which is recommended as the preferred anesthesia auxiliary scheme.

To investigate the efficacy and safety of programmed death-1 (PD-1) inhibitor targeted therapy combined with the oxaliplatin+5-fluorouracil+calcium leucovorin (mFOLFOX6) chemotherapy regimen in the preoperative neoadjuvant treatment of locally advanced middle-low rectal cancer.

Elderly patients with locally advanced middle-low rectal cancer were divided into control group and treatment group according to the treatment method. Patients in the control group received the conventional mFOLFOX6 chemotherapy regimen, with one cycle every 2 weeks for a total of 4 cycles. Patients in the treatment group received the conventional neoadjuvant chemotherapy with the mFOLFOX6 regimen combined with the PD-1 inhibitor camrelizumab injection (200 mg intravenously infused on day 1 of each cycle), with one cycle every 2 weeks for a total of 4 cycles. The surgical intervention was undertaken 4-6 weeks following completion of the chemotherapy regimen. The short-term efficacy evaluation of solid tumors, malignant tumor markers, anorectal dynamics and surgical efficiency were compared between the two groups and the safety was evaluction.

A total of 97 patients were recruited, with 54 assigned to the control group and 43 in the treatment group. After treatment, the objective response rates (ORR) were 25.93% (14 cases/54 cases) in the control group and 48.84% (21 cases/43 cases) in the treatment group; the disease control rates (DCR) were 57.41% (31 cases/54 cases) in the control group and 76.74% (33 cases/43 cases) in the treatment group, with statistically significant differences (P<0.05). After treatment, the carcinoembryonic antigen (CEA) levels in the control group and treatment group were (3.27±0.48) and (2.75±0.43) μg·L^-1, respectively; the carbohydrate antigen 199 (CA199) levels were (22.19±3.17) and (19.80±2.94) KU·L^-1, respectively. The above indicators demonstrated statistically significant differences between the treatment and control groups (all P<0.001). After treatment, the rectal resting pressure (RRP) levels in the control group and treatment group were (11.36±1.75) and (13.95±2.03) mmHg, respectively; the maximal tolerable rectalvolume (MTV) levels were (142.97±18.39) and (135.43±15.96) mL, respectively; the rectal compliance (RC) levels were (3.13±0.58) and (2.75±0.39) mL·mmHg^-1, respectively. The above indicators demonstrated statistically significant differences between the treatment and control groups (all P<0.05). The incidence of postoperative complications was 20.37% (11 cases/54 cases) in the control group and 18.60% (8 cases/43 cases) in the treatment group, with no statistically significant difference (P>0.05).

Preoperative targeted therapy with a PD-1 inhibitor combined with the mFOLFOX6 chemotherapy regimen can significantly improve the short-term efficacy of solid tumors, reduce tumor marker levels, optimize anorectal dynamics and quality of life in patients with locally advanced middle-low rectal cancer, with mild immunosuppression and good safety.

To analyze the occurrence and risk factors of acute kidney injury (AKI) in patients with hematologic malignancies who experienced severe delayed excretion after high-dose methotrexate (HD-MTX) chemotherapy, and to explore dose adjustment strategies for reusing HD-MTX in these patients.

A retrospective analysis was conducted on clinical data of hematologic malignancy patients treated with HD-MTX in the hematology and oncology departments. Patients with severe delayed MTX excretion (defined as serum MTX >30 μmol·L^-1 at 24 h, >3 μmol·L^-1 at 48 h, >0.3 μmol·L^-1 at 72 h, or prolonged low-level MTX >0.3 μmol·L^-1 for >6 days) were included. Patients were divided into three groups based on AKI severity, group A was mild AKI, group B was moderate AKT, group C was severe AKI. Statistical methods were used to analyze risk factors for severe excretion delay and AKI.

Among 26 patients (28 HD-MTX cycles) with severe delayed excretion, AKI occurred in all cycles (100.00%). Group A accounted for 21.43% (6 cases/28 cases), Group B accounted for 46.43% (13 cases/28 cases), accounted for 32.14% (9 cases/28 cases). Pre-treatment albumin levels in group A, group B and group C were (42.22±4.63), (39.08±4.3) and (35.25±4.19) g·L^-1. Among patients with moderate/severe AKI, 11 received 19 subsequent HD-MTX cycles at reduced doses (1/3-1× original), with no recurrence of excretion delay or AKI.

Low pre-treatment albumin levels, particularly <35 g·L^-1 are strongly associated with severe MTX-related AKI. Patients with a history of MTX-induced AKI can safely reuse HD-MTX at adjusted doses (based on renal recovery and clinical indicators) without AKI recurrence.

To observe the efficacy and safety of mycophenolate mofetil capsules combined with belimumab injection in the treatment of systemic lupus erythematosus (SLE) with acute kidney injury (AKI).

Patients were divided into control group and treatment group according to random number table method. The control group was treated with mycophenolate mofetil capsules, mycophenolate orally, 0.5 g per time, twice a day. The treatment group was treated with belimumab injection on the basis of control group. Take 10 mg·kg^-1 belimumab injection, dissolve in 250 mL normal saline, intravenous infusion, once every 2 weeks for the first 3 times, and once every 4 weeks thereafter. Both groups were treated for 6 months. Symptom score, inflammatory injury index, renal function index, immune function and clinical efficacy were compared between the two groups, and safety evaluations conducted.

A total of 197 cases were screened, with 127 cases enrolled. The treatment group consisted of 63 cases and the control group consisted of 64 cases. In control group, 4 cases dropped out due to mid course transfer, and 60 cases were included. In treatemnt group, 4 cases dropped out due to giving up treatment, and 59 cases were included. After treatment, the British isles lupus assessment group (BILAG) scores in treatment group and control group were (12.05±2.14) and (17.24±3.27) points, respectively; the systemic lupus erythematosus disease activity index (SLEDAI) scores were (6.41±1.33) and (9.25±1.98) points, respectively; the levels of mannose-binding lectin (MBL) were (62.09±6.10) and (78.34±8.51) ng·L^-1, respectively; the levels of serum creatinine (Scr) were (172.20±21.08) and (228.36±25.42) μmol·L^-1, respectively; the levels of blood urea nitrogen (BUN) were (10.07±1.96) and (15.24±3.17) mmol·L^-1, respectively; the levels of immunoglobulin M (IgM) were (1.17±0.21) and (2.19±0.30) g·L^-1, respectively; the levels of IgG were (5.93±0.89) and (4.87±0.65) g·L^-1, respectively. The above indicators in treatment group showed statistically significant differences compared to control group (all P<0.05). The total clinical effective rates of treatment group and control group were 88.14% (52 cases/59 cases) and 71.67% (43 cases/60 cases), respectively, with treatment group significantly higher than control group (P<0.05). The main adverse drug reactions of control group were elevated transaminase levels, nausea, vomiting and diarrhea; treatment group mainly had elevated transaminase levels, nausea and vomiting, vascular edema and diarrhea. The total incidence of adverse drug reactions in control group and treatment group were 10.00% (6 cases/60 cases) and 13.56% (8 cases/59 cases), respectively, with no statistically significant difference (P>0.05).

Mortimycophanate capsules combined with belimumab injection in the treatment of SLE patients with AKI is effective, can improve clinical symptoms and renal function, reduce inflammation, improve immune function, and has good safety.

To analyze the steady state plasma concentrations and dose-corrected concentration(C/D) influencing factors of vortioxetine tablets in patients with depression, and to provide guidance in the practice of rational clinical use of vortioxetine tablets in patients with depression.

Patients with depression who took vortioxetine and underwent therapeutic drug monitoring of blood concentrations in our hospital from March 2022 to November 2024 were selected as the study subjects, and their blood concentrations were monitored. Laboratory indicators, demographic information and the effect of coadministration on dose-corrected concentrations of vortioxetine tablets were statistically analyzed by SPSS 26.0.

A total of 90 patients were enrolled, and 107 sessions of blood concentration monitoring were performed. In depressed patients, the steady state plasma concentration was (28.05±20.28) ng·mL^-1, the administered daily dose was (14.86 ± 5.21) mg·d^-1, and the dose-corrected concentration was (1.96±1.24) ng·mL^-1·mg^-1·d. 69.16% (74 cases/107 cases) of C/D exceeded the upper limit of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie(AGNP) guideline reference range. The body weight, alanine aminotransferase(ALT), and urea, as well as the combination of paliperidone, aripiprazole, or clozapine all had a significant effect on the dose-corrected concentration of vortioxetine (all P<0.05). Multiple linear regression analysis revealed that body weight and the combination of aripiprazole had a significant effect on vortioxetine C/D (F=8.517, R²=0.148, P<0.001).

When vortioxetine is used clinically, the dosage should be adjusted according to the patient’s body weight. When it is used in conjunction with aripiprazole, regular monitoring of the plasma concentration should be carried out.

To observe the clinical efficacy and safety of polymyxin B injection combined with sitafloxacin tablets in the treatment of hospital-acquired pneumonia (HAP) caused by extensively drug-resistant Pseudomonas aeruginosa.

Patients with pandrug-resistant pseudomonas aeruginosa (PDR-PA) pneumonia admitted to our hospital were enrolled. According to treatment regimen, patients were divided into control group and treatment group. Patients in the control group received polymyxin B injection at an initial dose of 2.0-2.5 mg·kg^-1, followed by a maintenance dose of 1.25-1.5 mg·kg^-1 every 12 h after the loading dose. Patients in the treatment group received additional oral sitafloxacin tablets at 50-100 mg twice daily on the basis of the above regimen. The duration of antibacterial treatment for both groups was 7 days in principle, with a maximum of 14 days. Clinical efficacy, bacterial clearance rate, inflammatory markers, arterial blood gas and oxygenation parameters, prognosis, and safety profiles were compared between two groups.

A total of 128 patients were included in this study, with 64 cases in each group. After treatment, the total effective rates in the control group and the treatment group were 76.56% (49 cases/64 cases) and 95.31% (61 cases/64 cases), showing a statistically significant difference (P<0.05). After treatment, the total bacterial clearance rates in control and treatment groups were were 73.44% (47 cases/64 cases) and 93.75% (60 cases/64 cases), respectively; the serum levels of procalcitonin (PCT) were (1.42±0.31) and (0.81±0.18) ng·mL^-1, respectively; C-reactive protein (CRP) were (68.14±15.62) and (38.27±12.46) mg·L^-1, respectively; and interleukin-6 (IL-6) were (61.73±14.85) and (38.92±11.77) pg·mL^-1, respectively; the arterial partial pressure of oxygen (PaO₂) were (75.36±7.15) and (88.57±6.93) mmHg, respectively; the arterial partial pressure of carbon dioxide (PaCO₂) were (45.27±4.86) and (39.68±4.25) mmHg, respectively; and the oxygenation index (PaO₂/FiO₂) were 236.48±28.51 and 278.36±31.22, respectively. All of these indicators in treatment group showed statistically significant differences compared to control group (all P<0.05). The 28-day all-cause mortality rates of the control group and the treatment group were 10.94% (7 cases/64 cases) and 4.69% (3 cases/64 cases), respectively; and the length of hospital stay were (15.82±4.27) and (14.97±3.58) d, respectively; with no significant differences between the two groups (all P>0.05). The incidences of total adverse drug reactions in the treatment group and the control group were 18.75% (12 cases/64 cases) and 25.00% (16 cases /64 cases), respectively, with no statistically significant difference between the two groups (P>0.05).

Polymyxin B injection combined with sitafloxacin tablets significantly improves bacterial clearance, reduces inflammatory response, and enhances oxygenation in patients with xDR-PA HAP, while maintaining good safety, indicating its potential clinical utility.

To explore the intervention effect of jiedu dihuang decoction on the inflammatory microenvironment of colon cancer by regulating mitophagy and nucleotide - binding oligomerization domain (NOD) like receptor hot protein domain-related protein 3 (NLRP3) inflammasome.

The animal model was successfully replicated by intraperitoneal injection of azoxymethane (AOM) combined with feeding dextran sodium sulfate (DSS). The animals were randomly divided into A: control group, B: model group, C, D, E: Jiedu Dihuang Decoction low, medium and high dose group, F: positive drug group. Ninety male C57BL/6 mice were randomly divided into 6 groups of 15 mice each, and all groups were treated continuously for 10 weeks. The pathological changes of rectal tissue were evaluated by hematoxylin-eosin (HE) staining. Immunofluorescence staining was used to observe the expression site and intensity of PTEN-induced kinase 1 (PINK1), Parkinson’s disease protein (Parkin) and B-cell lymphoma-2-interacting myosin-like coiled-coil protein 1 (Beclin1) in colon tissue. The expression of NLRP3, apoptosis-associated speck-like protein (ASC) and Caspase-1 mRNA in rectum was detected by polymerase chain reaction (PCR). The protein expression levels of PINK1, Parkin, Beclin1, NLRP3, ASC and Caspase-1 were detected by Western blotting (WB). The ratio of helper T cell 1 (Th1) to helper T cell 2 (Th2) was detected by flow cytometry. The levels of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were detected by enzyme-linked immunosorbent assay (Elisa).

The mRNA expression levels of NLRP3, ASC and Caspase-1 in the model group were 2.06±0.22, 3.03±0.16 and 3.28±0.22, respectively, while those in the control group were 1.01±0.17, 1.01±0.19 and 1.00±0.11, respectively, with statistically significant differences between the two groups (all P<0.01). The mean fluorescence intensities of PINK1, Parkin and Beclin1 in the model group were 76.39±4.89, 83.12±5.01 and 87.43±3.77, respectively, compared with 122.99±6.93, 138.38±3.84 and 143.22±9.42 in the control group, and the differences were statistically significant (all P<0.01). As for the proportion of T helper cells in peritoneal fluid, the model group showed a significantly lower Th1 proportion (0.74±0.09)% and a significantly higher Th2 proportion (2.05±0.26)% compared with the control group [(4.78±0.62)% and (0.26±0.07)%, respectively, all P<0.01]. In terms of peripheral blood cytokine levels, the concentrations of IL-4, IL-6, IL-10 and TNF-α in the model group were (48.98±3.78) pg·mL^-1, (44.42±2.55) pg·mL^-1, (37.67±5.34) pg·mL^-1 and (79.11±6.32) pg·mL^-1, respectively, which were significantly higher than those in the control group [(26.44±5.64) pg·mL^-1, (24.21±2.25) pg·mL^-1, (19.06±3.76) pg·mL^-1 and (35.78±13.17) pg·mL^-1, respectively]. Conversely, the levels of IL-12 and IFN-γ in the model group were (28.28±2.33) ng·mL^-1 and (238.67±35.78) pg·mL^-1, respectively, which were significantly lower than those in the control group [(55.39±3.47) ng·mL^-1 and (517.72±52.15) pg·mL^-1, respectively], with all differences reaching statistical significance (all P<0.01). The mRNA expression levels of NLRP3 in the low, medium, high-dose Jiedu-Dihuang Decoction groups and the positive drug group were 1.75±0.10, 1.59±0.11, 1.31±0.11 and 1.48±0.10, respectively; the mRNA expression levels of ASC were 2.69±0.10, 1.96±0.14, 1.54±0.18 and 1.89±0.09, respectively; and the mRNA expression levels of Caspase-1 were 2.85±0.08, 2.24±0.26, 1.58±0.22 and 1.94±0.16, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant (P<0.05, P<0.01). The mean fluorescence intensities of PINK1 in each treatment group were 87.50±9.38, 98.75±7.13, 107.28±6.60 and 94.75±7.11, respectively; those of Parkin were 94.11±8.17, 103.13±8.59, 111.27±9.66 and 101.27±9.21, respectively; and those of Beclin1 were 100.2±7.11, 107.92±6.84, 122.65±8.36 and 105.44±7.55, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant(P<0.05, P<0.01). The proportions of Th1 in peritoneal fluid of each treatment group were (1.34±0.13)%, (1.78±0.21)%, (2.89±0.23)% and (2.47±0.24)%, respectively; and the proportions of Th2 were (1.65±0.18)%, (1.06±0.11)%, (0.57±0.14)% and (0.68±0.07)%, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant (all P<0.05, P<0.01). The levels of IL-4 in peripheral blood of each treatment group were (41.67±4.31), (36.39±5.93), (33.61±4.30) and (33.94±5.81) pg·mL^-1, respectively; those of IL-6 were (39.10±2.89), (32.85±3.98), (28.91±1.91) and (27.63±1.98) pg·mL^-1, respectively; those of IL-10 were (32.11±7.50), (26.28±4.65), (23.22±4.35) and (26.22±6.15) pg·mL^-1, respectively; those of TNF-α were (64.13±13.12), (57.44±13.62), (47.45±10.06) and (50.78±10.9) pg·mL^-1, respectively; those of IL-12 were (34.09±2.49), (38.53±3.84), (42.67±3.87) and (41.93±4.39) ng·mL^-1, respectively; and those of IFN-γ were (286.57±54.77), (358.59±52.15), (435.28±73.12) and (405.33±39.33) pg·mL^-1, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant(all P<0.05, P<0.01)

Jiedu-Dihuang Decoction can improve the inflammatory microenvironment of colon cancer, which may be related to the regulation of NLRP3 inflammasome by mitochondrial autophagy.

To develop a transdermal delivery system for tetraphydrocurcumin nanoemulsion-gel (Thc@NE@gel), and to investigate its therapeutic efficacy and mechanism of action in atopic dermatitis (AD).

Thc@NE@gel was prepared using a high-energy emulsification method combined with a low-temperature swelling process. The formulation was characterized for particle size, zeta potential, drug loading, encapsulation efficiency, morphology and physicochemical properties. In vitro transdermal absorption experiments were conducted using a Franz diffusion cell. An AD mouse model was established, and successfully induced mice were randomly divided into animal control group, positive drug group (10mg·kg^-1 dexamethasone gel), animal model group, Thc@NE group (Thc@NE 20 mg·kg^-1) and animal Thc@NE@gel low-, medium- and high-dose experimental groups (10, 20, and 30 mg·kg^-1 Thc@NE@gel), with 6 mice in each group. Body weights of mice in each group were measured and changes recorded; hematoxylin and eosin (HE) staining was performed to observe histopathological damage in skin tissue; enzyme-linked immunosorbent assay (ELISA) was used to detect serum inflammatory cytokine levels. Concurrently, an in vitro inflammatory model was established using human immortalized keratinocytes (HaCaT). Cells were divided into cell control group, cell model group (LPS 1 μg·mL^-1), cell low- and high-dose Thc@NE@gel expreimental groups (10 and 30 μM Thc@NE@gel). Reactive oxygen species (ROS) were measured in each group using flow cytometry; serum inflammatory cytokine levels were detected by ELISA; Western blot analysis was performed to detect the expression of key proteins in the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway.

Thc@NE@gel was developed with a particle size of (195.30±5.20) nm, a zeta potential of (-24.51±1.45) mV, and a encapsulation efficiency of (72.70±0.67)%. The body weights of mice in the animal Thc@NE@gel low-, medium-, and high-dose treatment groups, the animal blank group, the animal model group, the Thc@NE group, and the positive control (dexamethasone) group on day 17 were (21.50±1.20), (22.30±1.15), (24.00±1.25), (26.20±1.30), (17.30±1.10), (18.20±1.15) and (17.50±1.05) g, respectively; immunoglobulin E(IgE) levels were (40.52±10.23), (32.84±9.65), (30.67±10.12), (21.23±3.45), (53.21±4.12), (56.45±5.89) and (64.32±12.14) ng·mL^-1; IL-17 levels were (48.23±8.12), (25.43±4.67), (30.21±9.87), (23.45±5.12), (84.56±12.34), (54.12±5.67), and (47.89±6.78) pg·mL^-1; IL-23 levels were (45.67±3.12), (44.23±2.98), (40.12±2.45), (25.34±7.12), (73.45±15.67), (55.23±6.78), and (24.56±1.89) pg·mL^-1; when comparing the animal animal model group with the animal blank group, all of the above inflammatory markers showed statistically significant differences (all P<0.05). Compared with the animal model group, the IgE and IL-17 levels in the animal medium- and high-dose groups of Thc@NE@gel, as well as the IL-23 levels in all dose groups, showed statistically significant differences (all P<0.05); the IgE levels in the positive control group showed no statistically significant difference compared with the animal model group (P>0.05). Furthermore, the relative protein expression levels of cGAS in the low-dose and high-dose cell Thc@NE@gel experimental groups, the cell blank group, and the cell model group were 1.15±0.12, 0.82±0.08, 1.00±0, and 1.65±0.18, respectively; the relative protein expression levels of STING were 0.95±0.10, 0.60±0.06, 1.00±0.00, and 1.65±0.15, respectively. Compared with the animal blank group, all of the aforementioned indicators in the cell model group showed statistically significant differences (all P<0.001).

Thc@NE@gel enhances the anti-inflammatory effects of Thc, providing new insights for the development of skin delivery systems for natural active ingredients; furthermore, by inhibiting the cGAS-STING pathway, Thc@NE@gel improves atopic dermatitis, offering a new mechanistic perspective for its treatment.

To establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining the plasma concentration of the active component polymyxin E in patients treated with colistimethate sodium.

Polymyxin B1 was used as an internal standard, and solid phase extraction (SPE) was employed to process the samples. The chromatographic column was a Kinetex C₁₈ (3 mm×100 mm, 2.6 μm). Mobile phase A was an aqueous solution containing 0.1% formic acid and 5 mmol·L^-1 ammonium acetate, and mobile phase B was a methanol solution containing 0.1% formic acid. Gradient elution was performed at a flow rate of 0.5 mL·min^-1. An electrospray ionization (ESI) source was used with positive ion multiple reaction monitoring (MRM) for detection. The ion pairs for quantitative analysis were as follows: m/z 585.6→241.1 (polymyxin E1), m/z 578.6→227.2 (polymyxin E2), and m/z 602.6→101.2 (polymyxin B1). The selectivity, standard curve, residues, precision and accuracy, extraction recovery rate, matrix effect and stability of the method were investigated, and the plasma concentrations of polymyxin E1 and E2 in patients treated with colistimethate sodium were measured.

The linear relationships of polymyxin E1 and E2 concentrations were good within the ranges of 0.02–3.86 μg·mL^-1 and 0.03–5.65 μg·mL^-1, respectively. The lower limits of quantification (LLOQ) for polymyxin E1 and E2 were 0.02 μg·mL^-1 and 0.03 μg·mL^-1, respectively. The standard curve equations for polymyxin E1 and E2 are Y=4.55×10^-1X-2.92×10^-2 (r=0.994 2)、Y=8.61×10^-1X-1.38×10^-2 (r=0.996 4), respectively. The within-day and day-to-day precision, accuracy, extraction recovery, matrix effects, and stability of polymyxin E1 and E2 all met the methodological requirements. Using this method, the AUC of polymyxin E in 26 patients receiving colistimethate sodium ranged from 28.42 to 317.51 μg·mL^-1.

This method is accurate, sensitive, rapid, and stable, and can be used for the determination of the plasma concentrations of polymyxin E1 and E2 in human plasma.

To investigate the etiological factors and clinical characteristics of statin-associated myopathy in elderly patients.

A retrospective analysis was performed on elderly patients with statina-ssociated myopathy who were treated in the internal medicine department of our hospital from January 2017 to June 2024. Data including etiology, clinical manifestations, treatment process and prognosis were collected and analyzed.

A total of 21 elderly patients with statina-ssociated myopathy were enrolled, including 13 males and 8 females, with an average age of (77.33±9.61) years. Among them, 5 patients were diagnosed with rhabdomyolysis. According to the type of statin taken, patients were divided into 5 groups: atorvastatin group, rosuvastatin group, simvastatin group, pitavastatin group and Xuezhikang group. All patients received monotherapy without overlapping or combined use of different statins. The duration of statin therapy at onset ranged from 2 weeks to 10 years. Precipitating factors included infection, concomitant medications, stress and exercise. Among them, 12 cases were related to infection (9 pneumonia, 2 urinary tract infections, 1 intestinal infection), and 2 cases were associated with concomitant medications (quetiapine and cyclosporine A, respectively). Most patients had multiple comorbidities: hypertension in 90.48% (19 cases/21 cases), type 2 diabetes mellitus in 66.67% (14 cases/21 cases), coronary heart disease in 47.62% (10 cases/21 cases), and chronic kidney disease in 23.81% (5 cases/21 cases). Patients were on multiple concomitant medications, with a mean of 6 drugs used. Acute kidney injury occurred in 4 patients with myopathy and in 5 patients with rhabdomyolysis. After comprehensive treatment including statin discontinuation, fluid replacement, urine alkalinization and blood purification, all patients improved and no deaths occurred. Serum creatinine in patients with acute kidney injury returned to normal or baseline levels before onset.

Elderly patients with acute infection, concomitant medications and multiple comorbidities should be closely monitored for the risk of statinassociated myopathy or rhabdomyolysis. Acute kidney injury is common in such elderly patients. Early discontinuation of statins and comprehensive treatment including symptomatic fluid infusion and blood purification can significantly improve patient prognosis.

To analyze the role mechanism of xuesaitong injection (lyophilized) in the treatment of cerebral infarction by network pharmacology and molecular docking technology.

The intersection targets of five important active ingredients (Ginsenoside Rg1, Ginsenoside Rb1, Ginsenoside Re, Notoginsenoside R1, Ginsenoside Rd) in xuesaitong injection (lyophilized) and acute cerebral infarction were screened by database, and the target action network was constructed. Gene ontology (GO) pathway analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed by using digital-audio-video internet devince (DAVID) database, and molecular docking verification was performed.

A total of 61 non-redundant targets were screened for Panax notoginseng saponins, and 5 737 non-redundant targets were identified for cerebral infarction. The intersection of three databases yielded 64 common targets. After intersecting the drug targets with the disease targets, two overlapping targets were obtained: protein kinase C beta (PRKCB) and tumor necrosis factor (TNF). Intersection with the non-redundant disease targets yielded 51 overlapping targets. Based on network topology parameters and the intersection target results, caspase-3 (CASP3), TNF, nuclear factor kappa B subunit 1 (NFKB1), matrix metalloproteinase-9 (MMP9), tumor protein p53 (TP53), and PRKCB were selected for subsequent molecular docking. The results of GO functional enrichment analysis showed that in terms of biological processes, the target genes were mainly involved in the positive regulation of gene expression, the negative regulation of apoptosis process, and the positive regulation of miRNA transcription. In terms of cell components, the target genes were mainly located in extracellular space, extracellular region, blood, axon and protein complex. In terms of molecular function, the target proteins mainly had the same protein binding, protease binding, Heat shock protein 90 (HSP90) protein binding and other functions, and the enrichment results were statistically significant (all P<0.05). The results of KEGG enrichment analysis revealed that the potential targets of xuesaitong injection (lyophilized) in the treatment of cerebral infarction were enriched in advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) signaling pathway, lipid and atherosclerosis, fluid shear stress and atherosclerosis, proteoglycans in cancer, MAPK signaling pathway, thyroid hormone signaling pathway, apoptosis pathway and other signaling pathways, and the enrichment results were statistically significant (P<0.05). The results of molecular docking displayed that the main active ingredients of xuesaitong injection (lyophilized) had good binding ability with the core target protein, among which Ginsenoside Rg1 had the lowest binding energy with TNF, and CASP3, PRKCB showed strong binding with various active ingredients.

Xuesaitong injection (lyophilized) may play a multi-target comprehensive role in the treatment of cerebral infarction by regulating CASP3, TNF, NFKB1, MMP9, TP53, PRKCB and other key targets, acting on pathways such as apoptosis, inflammation and atherosclerosis.

To systematically elucidate the mechanism of action of Qizhi hypoglycemic tablets (QZT) in treating diabetic vascular complications, this study adopted the methods of network pharmacology and molecular docking.

Active ingredients and their corresponding targets of QZT were retrieved from traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) and other databases. Disease targets related to diabetic nephropathy, retinopathy, and peripheral neuropathy were collected from The human gene database (GeneCards) and online mendelian inheritance in man (OMIM). Overlapping targets between drugs and diseases were identified, and a protein-protein interaction (PPI) network was constructed. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were performed using the database for annotation, visualization, and integrated discovery (DAVID). Molecular docking was used to validate the binding interactions between key active components and core targets.

A total of 116 active ingredients, 2 245 disease-related targets, and 354 common targets were obtained. Core targets such as proto-oncogene tyrosine-protein kinase (SRC), signal transducer and activator of transcription 3 (STAT3), estrogen receptor 1 (ESR1), and RAC-alpha serine/threonine-protein kinase (AKT1) were identified. GO and KEGG analyses revealed that the therapeutic effects of QZT were primarily mediated through key pathways including phosphatidylinositol 3-kinase/Akt signaling pathway (PI3K-Akt) and advanced glycation end products-receptor for advanced glycation end products signaling pathway (AGE-RAGE). Molecular docking confirmed stable binding of core components including apigenin, baicalein, and 4′,7-dihydroxyflavanone (DFV) to the core targets.

This study preliminarily clarifies the multi-component, multi-target, and multi-pathway mechanism of QZT against diabetic vascular complications, providing a theoretical basis for its clinical application and further investigation.

To analyze the gene polymorphism of aspirin drug-related genes platelet membrane glycoprotein Ⅲa phospholipase A2 (GPⅢa PLA2), platelet endothelial aggregation receptor 1 (PEAR1), glutathione S-transferase P1 (GSTP1) and prostaglandin endoperoxide synthase 1 (PTGS1) in patients with ischemic stroke in Beijing.

Patients with ischemic stroke in the neurology department of our hospital were included as research subjects, and the polymorphism of drug-related gene loci was detected by fluorescence in situ hybridization sequencing.

The overall mutation rate of aspirin related genes was 75.42% (356 cases/472 cases). GPⅢa PLA 2 typing included 458 cases TT type, 11 cases TC type and 3 cases CC type, C allele frequency was 1.80% (17 cases/944 cases); PEAR1 typing included 187 cases GG type, 224 cases GA type and 61 cases AA type, A allele frequency was 36.65% (346 cases/944 cases); GSTP1 typing included 295 cases AA type, 160 cases GA type and 17 cases GG type, G allele frequency was 20.55% (194 cases/944 cases); typing of PTGS1 included 50 cases AA type, and the frequency of G allele was 0. GPⅢa PLA2 TT+PEAR1 GA+GSTP1 AA was the most common combination, accounting for 138 cases (29.24%). There was no statistically significant difference in gene polymorphisms of GPⅢa PLA2, PEAR1, GSTP1 between different genders and ages (all P>0.05). The genotype and allele distributions of GPⅢa PLA2, PEAR1, GSTP1 and PTGS1 in patients with ischemic stroke in Beijing were not statistically significantly different from those in Zaozhuang, Nanjing and Shanghai (all P>0.05), while the genotype and allele distributions of GPⅢa PLA2, PEAR1 and GSTP1 were statistically significantly different from those in Guangdong (all P<0.05).

PEAR1 and GSTP1 are the main mutations in aspirin drug-related genes in patients with ischemic stroke in Beijing. The mutation ratio of GPⅢa PLA2 and PTGS1 gene is low, and the gene polymorphism in Beijing is different from that in other regions.

To systematically evaluate the efficacy and safety of lecarnitine in the treatment of patients with myocardial damage.

Search databases such as PubMed, Embase, Cochrane Library, CNKI, Wanfang Database, etc. randomized controlled trials (RCTS) comparing L-carnitine with sodium creatine phosphate, sodium fructobisphosphonate, trimetazidine and coenzyme Q10 for the treatment of myocardial damage were included according to the inclusion and exclusion criteria. The search period for all was from the establishment of the database to May 2024. Meta-analysis was performed using RevMan 5.3 and Stata 14.0.

A total of 12 RCTs were included, involving a total of 1 408 patients. Meta-analysis showed that the total effective rate of levocarnitine was 89.53% (556 cases/621 cases), which was significantly higher than that [83.98% (519 cases/618 cases)]of the control group [OR=1.83, 95% CI (1.10~3.06), P<0.05]; the incidence of adverse drug reactions of levocarnitine and the control group was 2.47% (9 cases/364 cases) and 3.31% (12 cases/362 cases) with no statistically significant difference [OR=0.83, 95% CI (0.17~4.18), P>0.05]. The creatine kinase (CK) levels of L-carnitine group and the control group were(203.04±34.59) and (238.28±33.97)U·L^-1, respectvely [OR=-26.81, 95% CI (-47.43~-6.18), P<0.01]; the creatine kinase isoenzyme MB (CK-MB) levels were (21.64±10.76) and (26.71±14.48)U·L^-1, respectvely [OR=-4.19, 95% CI (-6.70~-1.67), P<0.001]were significantly better than those of . There was no statistically significant difference in the levels of lactate dehydrogenase (LDH) and cardiac troponin Ⅰ (cTnⅠ) of L-carnitine compared with the control group (all P>0.05).

The effectiveness of levocarnitine in the treatment of myocardial damage is relatively good, and there are no obvious adverse reactions.

To provide practical references for all participants in drug clinical trials on drug safety risk management and promote the construction of a more efficient clinical trial safety management system.

Based on the regulatory practice of 40 clinical trial safety risk control cases from the Center for Drug Evaluation in 2024, this paper uses classified statistics and correlation analysis methods to analyze the characteristics of safety risk information from multiple dimensions such as drug types and indications, and systematically sorts out the response logic of regulatory measures.

Among the 40 cases where risk management procedures were initiated, distinct risk characteristics were observed across different drug types and indications. The regulatory measures reflected the principle of matching the intensity of control with the risk characteristics.

Regulatory authorities have adopted differentiated regulatory requirements in accordance with the logic of risk classification and bottom-line thinking. The regulatory initiatives have gradually evolved into focusing on the optimization and full-chain improvement of sponsors’ risk management systems, providing crucial support for the protection of subjects’ rights and interests as well as the high-quality development of pharmaceutical innovation..

This study aimed to evaluate analyze the current quality status of investigator-initiated trials (IITs) conducted in a hospital, analyze key influencing factors, explore targeted improvement measures, and provide references for enhancing the design level of IITs.

IITs registered in the Medical Research Registration and Filing Information System by the hospital from January 2020 to April 2025 were selected as the research objects. The research compliance, scientificity, and value were assessed, and then followed by statistical analysis.

Among the 124 IITs, 76% were initiated by investigators with associate senior titles or above. The median scores of the standardization and scientificity dimensions were both 8 points, while the median score of the research value dimension was 6 points. The total scores of interventional studies and observational studies were 23 and 21, respectively (P<0.01), and the total scores of multi-center studies and single-center studies were 23 and 20, respectively (P<0.001). Except for the correlation between funding support and the scientificity score, which the difference was not statistially signifccant (P>0.05), funding support showed a significant positive correlation with both the research compliance and research value dimensions (correlation coefficients ranging from 0.300 to 0.346, all P<0.001); disciplinary strength, and investigator title were significantly positively correlated with all three dimensions of research quality (correlation coefficients ranging from 0.213 to 0.380, P<0.01, P<0.001) and disciplinary strength had the greatest impact on research value.

Medical institutions still need to strengthen the standardization and scientificity of IITs, and there is great room for improvement in research value. Disciplinary strength, investigator background, and funding support are key factors affecting the research quality. From the perspective of institutional management, the quality of IITs can be effectively improved by constructing a systematical management system that integrates scientific review, methodological support and resource guarantee.